3rd European Workshop on
Skin Immune Mediated Inflammatory Diseases (SIMID)
24 September 2020 - 24 March 2021

Abstracts

Online submission of Abstract opens: June 15th
Abstract submission deadline: September  3rd

The Scientific Committee invites authors to submit their abstracts for consideration and inclusion in the e-learning materials of DIGITAL SIMID as e-poster.

IMPORTANT RULES FOR PRESENTERS

-The data of the abstract must be original and not previously published.
-The use of commercial drug names, brands and registered trademarks is strictly prohibited. Drugs should be referred to the active substance or pharmacological designation, we kindly recommend to use generic names. No mention of pharmaceutical company names should be included in the abstract either.
-Abstract must be submitted in english.
-Submission of an abstract implies that it has been approved by all listed authors.
-At least one author (the first or the presenting author) must register at the DIGITAL SIMID after receiving notification of acceptance.
-Only elettronic submission will be accepted. Faxed or emailed abstracts will not be reviewed.

PREPARATION OF YOUR ABSTRACT

The size of the abstract is limited to 3,000 characters (spaces and pictures are not taken in consideration).

The submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.

The template of the abstract is structured as following:

TITLE (as brief as possible but long enough to clearly indicate the nature of the study)

BODY:

-Introduction & Objectives-A sentence describing the purpose of the study
-Materials & Methods-Describe a selection of observations or experimental subjects
-Results-Describe results in a logical sequence
-Conclusions-Emphasize new and important aspects of the study and conclusions that are drawn from them

SELECTION OF ABSTRACTS AND NOTIFICATION OF ACCEPTANCE

Notification of acceptance will be sent to the submitting author. Please note that only the submitting author will receive email concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors, whose abstracts have been accepted, will receive instructions for the presentation of their abstracts or for their e-posters realization.